187 related articles for article (PubMed ID: 31117042)
1. New Biosimilar Approvals for Myeloid Growth Factors and Anemia.
Lyman GH
J Natl Compr Canc Netw; 2019 May; 17(5.5):622-624. PubMed ID: 31117042
[TBL] [Abstract][Full Text] [Related]
2. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.
Covic A; Abraham I
Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
Shah HH; Fishbane S
Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of biosimilar epoetins in nephrology in the United States.
Fishbane S; Shah HH
Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
[TBL] [Abstract][Full Text] [Related]
5. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
Kalantar-Zadeh K
Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
[TBL] [Abstract][Full Text] [Related]
6. The rise of biosimilars: How they got here and where they are going.
Patel D; Gillis C; Naggar J; Mistry A; Mantzoros CS
Metabolism; 2017 Oct; 75():45-53. PubMed ID: 28939017
[TBL] [Abstract][Full Text] [Related]
7. Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
Goldsmith D; Dellanna F; Schiestl M; Krendyukov A; Combe C
Clin Drug Investig; 2018 Jun; 38(6):481-490. PubMed ID: 29500617
[TBL] [Abstract][Full Text] [Related]
8. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
Aapro M; Krendyukov A; Schiestl M; Gascón P
BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
[TBL] [Abstract][Full Text] [Related]
9. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: are they ready for primetime in the United States?
Hirsch BR; Lyman GH
J Natl Compr Canc Netw; 2011 Aug; 9(8):934-42; quiz 943. PubMed ID: 21900222
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
13. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar growth hormone.
Saenger P
Indian J Pediatr; 2012 Jan; 79(1):92-8. PubMed ID: 22108957
[TBL] [Abstract][Full Text] [Related]
15. New alternatives in anemia treatment: biosimilars and HIF stabilizers.
Krishnan M; Nissenson AR
Nephrol News Issues; 2014 May; 28(6):24-8. PubMed ID: 24908823
[No Abstract] [Full Text] [Related]
16. Analytic characterization of biosimilars.
Sullivan PM; DiGrazia LM
Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
18. The US Biosimilar Market: Stunted Growth and Possible Reforms.
Sarpatwari A; Barenie R; Curfman G; Darrow JJ; Kesselheim AS
Clin Pharmacol Ther; 2019 Jan; 105(1):92-100. PubMed ID: 30415479
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.
Dingermann T; Scotte F
Expert Opin Biol Ther; 2016 Jul; 16(7):967-74. PubMed ID: 27227424
[TBL] [Abstract][Full Text] [Related]
20. Biosimilar biologic drugs: a new frontier in medical care.
Geynisman DM; De Velasco G; Sewell KL; Jacobs I
Postgrad Med; 2017 May; 129(4):460-470. PubMed ID: 28343424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
